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A B S T R A C T
Valvular calcification (VC) in chronic kidney disease is frequent, although most information 
derives from prevalent dialysis patients. There are few studies that analyse VC in patients 
who start dialysis.
Objective: To analyse the presence of VC at the start of dialysis and its relationship with events 
and/or death from cardiovascular causes in the course of follow-up.
Methods: In the study, we included patients who started dialysis between November 2003 
and September 2007. In the first month of treatment, we assessed the presence of VC by 
Doppler echocardiography, along with demographic factors and risk factors for cardiovascular 
disease, coronary artery disease, stroke, atrial fibrillation (AF), and cardiac dimensional 
and functional electrocardiographic and echocardiographic parameters. The biochemistry 
values assessed were: haemoglobin, calcium/phosphorous/iPTH metabolism, cholesterol 
and fractions, triglycerides, troponin I, albumin, CRP and glycosylated haemoglobin. We 
analysed the association between VC and the presence of myocardial infarction (MI), stroke 
and/or death from cardiovascular causes up to transplantation, death or the end of the 
study (December 2012).
Results: Of 256 enrolled patients (83% haemodialysis, 17% peritoneal dialysis), 128 (50%) 
had VC (mitral: 39, aortic: 20, both: 69). In the multivariate analysis, VC was associated with 
older age (OR: 1.110; 95% CI: 1.073–1.148; p = 0.000) and lower albumin levels (OR: 0.29; 95% 
CI: 0.14–0.61; p = 0.001). In a follow-up lasting 42.1 ± 30.2 months (898.1 patient-years), 68 
patients suffered MI, stroke and/or died from cardiovascular causes. In the Cox regression 
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patients, in which the prevalence of VC is greater than 30% of 
patients3,4,5. In these studies, VC correlates with the time on 
replacement therapy, inflammation, malnutrition and ath-
erosclerotic heart disease6,7,8,9,10. VC has been a predictor 
for mortality from cardiovascular causes and from any other 
cause3 in some studies, although not in all of them11.
VC and atherosclerosis are frequently observed in a same 
patient on dialysis, and the association between them has 
been demonstrated7,12. Based on this association, VC has been 
Introduction
The presence of cardiac valvular calcifications (VC) in chronic 
kidney disease (CKD) is considered a frequent fact. Population 
studies have confirmed an association between CKD and 
mitral or aortic VC from initial stages of decreased glomeru-
lar filtration1,2. Nevertheless, most publications derive from 
studies of prevalent peritoneal dialysis and haemodialysis 
 analysis, older age (HR: 1.028; 95% CI: 1.002–1.055; p = 0.037), coronary artery disease and/or 
stroke (HR: 1.979; 95% CI: 1.111–3.527; p = 0.021), AF (HR: 2.474; 95% CI: 1.331–4.602; p = 0.004), 
and the presence of VC at the start of dialysis (HR: 1.996; 95% CI: 1.077–3.700; p = 0.028) were 
the predictor variables for the occurrence of the analysed events.
Conclusions: The prevalence of VC at the start of dialysis is high and its presence predicts the 
occurrence of events and/or cardiovascular death in the course of follow-up.
© 2015 Sociedad Española de Nefrología. Published by ELSEVIER ESPAÑA, SLU. Published 
under the terms of the CC BY-NC-ND Licence(http://creativecommons.org/licenses/
by-nc-nd/4.0).
Las calcificaciones valvulares al inicio de diálisis predicen la aparición 
de eventos cardiovasculares en la evolución
R E S U M E N
La calcificación valvular (CV) en la enfermedad renal crónica es frecuente, aunque la mayor 
parte de la información procede de pacientes prevalentes en diálisis. Son pocos los estudios 
que analicen la CV en los pacientes que inician diálisis.
Objetivo: Analizar la presencia de CV al inicio de diálisis y su relación con eventos y/o muerte 
cardiovascular en la evolución.
Métodos: Incluimos en el estudio los pacientes incidentes en diálisis entre nov/03 y sept/07. 
En el 1º mes de tratamiento analizamos la presencia de CV mediante Ecocardiograma-
doppler, junto a factores demográficos y de riesgo cardiovascular, enfermedad coronaria, 
accidente cerebrovascular (ACV), fibrilación auricular (FA) y parámetros de electro y 
ecocardiográficos dimensionales y funcionales cardiacos. Los valores bioquímicos analizados 
fueron: hemoglobina, metabolismo calcio/fósforo/iPTH, colesterol y fracciones, triglicéridos, 
troponina I, albúmina, PCR y hemoglobina glicosilada. Analizamos la asociación de la CV 
con la presentación de infarto de miocardio (IAM), ACV y/o muerte cardiovascular hasta el 
trasplante, muerte, o fin del estudio (dic/2012).
Resultados: De 256 pacientes incluidos (83% hemodiálisis, 17% diálisis peritoneal), 128 
(50%) presentaban CV (mitral: 39, aórtica: 20, ambas: 69). En el análisis multivariante la CV 
se asoció a mayor edad (OR: 1,110; IC 95%: 1,073-1,148; p = 0,000) y menor albúmina (OR: 
0,29; IC 95%: 0,14-0,61; p = 0,001). En un seguimiento de 42,1 ± 30,2 meses (898,1 pacientes-
año), 68 pacientes presentaron IAM, ACV y/o murieron por causa cardiovascular. En el 
análisis de regresión de Cox, la mayor edad (HR: 1,028; IC 95%: 1,002-1,055; p = 0,037), la 
enfermedad coronaria y/o ACV (HR: 1,979; IC95%: 1,111-3,527; p = 0,021), la FA (HR: 2,474; 
IC 95%: 1,331-4,602; p = 0,004) y la presencia de CV antes de entrar en diálisis (HR: 1,996; 
IC 95%: 1,077-3,700; p = 0,028), fueron predictores independientes de la presentación de 
los eventos analizados.
Conclusiones: La prevalencia de CV en el momento de iniciar diálisis es alta y su presencia 
predice la presentación de eventos y/o muerte cardiovascular en la evolución.
© 2015 Sociedad Española de Nefrología. Publicado por ELSEVIER ESPAÑA, SLU. Publicado 
bajo los términos de la licencia CC BY-NC-ND (http://creativecommons.org/licenses/
by-nc-nd/4.0).
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of qualitative variables, the Pearson’s Chi-square test was 
used. For the analysis of the association between VC and the 
risk factors that were present at the start of treatment, a logis-
tic regression multivariate analysis was performed, and the 
odds ratio (OR) and 95% confidence interval were obtained. 
The predictive power of variables for the occurrence of the 
endpoint of our study was analysed through a Cox propor-
tional-hazard regression analysis. The prognostic variable 
was the occurrence of the endpoint defined in the Methods 
section. Predictive variables were the presence of VC, and 
other variables with significant association in the univariate 
analysis or of special significance. The hazard ratio (HR) and 
95% confidence interval were obtained. 
Event-free survival was analysed with the Kaplan-Meier 
method, and the Mantel-Haenszel test (log-rank) was used to 
compare survival curves. For hypothesis contrast tests, a 
value of p < 0.05 was considered statistically significant. The 
analyses were carried out with the statistical package SPSS 
15.0 for Windows.
Results
Following the exclusion criteria, 48 patients were not included; 
another 29 patients were not included since they could not 
participate in the entire initial study. The total number of 
enrolled patients was 256. Mean age was 65.1 ± 15.9 years, 
median age was 69.9, and 146 patients (57%) were male. 
Nephropathies induced by renal failure included the follow-
ing: glomerulonephritis 17.2%; interstitial nephropathies 
15.2%; nephrosclerosis 15.6%; polycystic kidney disease 6.3%; 
other familial diseases 1.2%; systemic diseases 5.1%; diabetes 
18.4%; unidentified diseases 18.8%; other 2.3%. Diabetes 
caused nephropathy or was a concomitant disease in 73 
(28.5%) patients. 
They study included 213 (83%) patients receiving haemo-
dialysis and 43 (17%) patients in peritoneal dialysis, with a 
mean age of 66.8 ± 14.8 and 56.5 ± 18.5 years, respectively (p 
= 0.004). Patients were monitored for 42.1 ± 30 months (range: 
0.23–109.4), with a follow-up of 898.1 patient-years.
Prevalence of Valvular Calcification
At the beginning of the dialysis programme, valvular calcifi-
cation (VC) was present in 128 patients, which accounts for a 
prevalence of 50%. The grades were: 90 mild (35.1%); 30 mod-
erate (11.7%); and 8 severe (3.1%). Calcification was present in 
the mitral valve in 39 (15.2%) patients, the aortic valve in 20 
(7.8%), and in both valves in 69 (27%) patients. 
Those patients who had valvular calcification were an 
average of 18 years older and were mostly women, diabetic 
patients, and had a history of cardiovascular events and diag-
nosis of atrial fibrillation. A higher proportion of patients 
included in the haemodialysis programme had valvular cal-
cification. Creatinine, albumin and phosphorous levels were 
lower, while pulse pressure and body mass index were higher 
(Table 1). They also had greater left ventricular mass and left 
atrial dimension and greater diastolic dysfunction (Table 2). 
considered one of the manifestations of atherosclerosis7,13. 
However, all patients with VC do not have atherosclerosis. 
This suggests that, although both processes share pathogenic 
mechanisms, their pathogenesis and possibly the risk they 
involve are not identical14.
There are few studies about VC in patients with advanced 
stages of CKD at the onset of replacement therapy15,16.
The purpose of this study was to analyse the presence of 
VC in patients who started dialysis for the first time and its 
relationship with the occurrence of events and cardiovascu-
lar mortality during follow-up.
Methods
We included patients diagnosed with stage 5 CKD, who started 
haemodialysis or peritoneal dialysis for the first time between 
November 2003 and September 2007 in our hospital centre. 
Patients who started treatment in another centre or had 
undergone prior renal transplantation were excluded. The 
observational period ranged from the first day of dialysis to 
termination due to transplantation, death, patient transfer 
outside our health area of influence, or the end of the study 
31 December 2012.
In the first month of dialysis, the following variables were 
assessed and included for analysis: demographic characteris-
tics; anthropometric measurements; pulse pressure; history 
of hypertension and/or antihypertensive treatment (HTN); 
diabetes with indication of drug treatment at any time of fol-
low-up; active smoking habit or cessation in the last 10 years; 
coronary artery disease documented by a history of myocar-
dial infarction (MI) or compatible coronary angiographic test; 
ischaemic or haemorrhagic stroke, documented by a neurol-
ogist and/or imaging test report; atrial fibrillation (AF) in any 
of its forms documented in a prior medical record or by an ECG 
finding; and, analytical variables, such as haemoglobin, min-
eral metabolism (calcium, phosphorous, PTH), urea, creati-
nine, troponin I, albumin, C-reactive protein (CRP), cholesterol 
and fractions, triglycerides and glycosylated haemoglobin. 
VC was studied with colour Doppler echocardiography by 
a single observer. It was defined as increased echo-refrin-
gence with a thickness > 1 mm at the level of the mitral or 
aortic annulus or leaf let. Three grades were established 
according to the calcification area: mild, when there were only 
small, isolated areas; moderate, when there were multiple 
areas; and severe, when calcification was extensive and dif-
fuse. It was analysed whether the calcification was limited to 
only one valve, mitral or aortic, or involved both. 
The endpoint of our study was the occurrence of one or 
several of the following events in the course of follow-up: MI, 
stroke or death from cardiovascular causes (defined as death 
due to heart failure), pulmonary thromboembolism, sudden 
death, mesenteric ischaemia or peripheral arterial ischaemia.
Statistical Analysis
The Student’s t-test or the nonparametric Mann-Whitney test 
was used for the comparison of means. For the comparison 
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2 ischaemic, and 1 patient also had MI; 13 sudden death; 9 
heart failure, cardiogenic shock or malignant arrhythmia; 
8 mesenteric ischaemia; 2 pulmonary thromboembolism; 
3 arterial ischaemia/lower limb amputation.
• Patients who had cardiovascular events: 18, of which 10 
were MI, 7 were strokes, and 1 patient had MI and stroke. 
Twelve of these patients died in the follow-up due to 
non-cardiovascular causes, one received a renal trans-
plant, and five were alive at the end of the study.
The 68 patients who experienced an endpoint event were 
older than the 188 patients who did not. Most were diabetic 
patients and patients with a history of AF, MI and/or stroke. 
In the echocardiographic test, they showed greater left ven-
tricular mass and left atrial dilation with less left ventricular 
ejection fraction. Valvular calcification was more frequent in 
these patients (Table 4).
In the Kaplan-Meier analysis, the event-free survival was 
shorter in patients with valvular calcification. This difference 
was maintained when the analysis was performed in the 192 
(75%) patients with no prior diagnosis of coronary artery dis-
ease, stroke or AF (Figure 1).
The occurrence of endpoint events increased according to 
the VC grade. In the absence of calcification, 13.2% of patients 
presented an event, 37% with mild or moderate grade and 75% 
of patients with severe grade (Figure 2).
In the Cox regression analysis, we included variables with 
statistical significance in the univariate analysis and others 
that were potentially associated with cardiovascular morbid-
ity-mortality, such as sex, haemoglobin, phosphorous, CRP 
Frequency of HT and smoking habit, calcium levels, iPTH, 
anaemia or dyslipidemia, and systolic function assessed by 
echocardiography were not different from those observed in 
patients who did not have valvular calcification.
In the multivariate logistic regression analysis, we included 
factors with statistical significance in the univariate analysis 
and other factors of potential involvement in the valvular 
calcification process: total cholesterol, HDL and LDL fractions, 
triglycerides, CRP, and left ventricular ejection fraction (LVEF). 
In this analysis, the factors independently related to the pres-
ence of VC were older age and lower albumin level (Table 3).
Occurrence of endpoint
During follow-up, 68 patients presented endpoint events of 
the study: MI, stroke, and/or death from cardiovascular 
causes. The distribution was as follows:
• Patients who died from cardiovascular causes: 50. Causes 
included: 8 MI; 7 stroke, of which 5 were haemorrhagic and 
Table 1 – Characteristics of patients with VC at the start 
of dialysis
Without VC 
(n = 128)
With VC 
(n = 128)
p
Age (years) 56.2 ± 17 74 ± 9 0.000
Sex: Female (%) 47 (36.7) 64 (50) 0.032
Technique: (Peritoneal 
Dialysis)
30 (69.8) 13 (10.2) 0.004
Diabetes (%) 26 (35.6) 47 (64.4) 0.004
Coronary Artery Disease (%) 6 (4.7) 15 (11.7) 0.040
Ischaemic stroke (%) 5 (3.9) 14 (10.9) 0.032
AF (%) 6 (4.7) 25 (19.5) 0.000
BMI (kg/m2) 26.7 ± 5.1 28.1 ± 5.2 0.043
Systolic BP (mmHg) 124.5 ± 22.4 133.6 ± 26.9 0.004
Diastolic BP (mmHg) 74.9 ± 12.9 71.2 ± 12.4 0.019
Pulse pressure 49.6 ± 18.7 62.4 ± 21.9 0.000
Glucose (mg/dL) 104.5 ± 39 121 ± 69 0.020
Troponin I (ng/ml) 0.03 ± 0.05 0.24 ± 1.07 0.030
Creatinine (mg/dL) 7.4 ± 2.3 5.9 ± 2.0 0.000
Phosphorous (mg/dL) 5.4 ± 1.8 4.8 ± 1.5 0.003
Albumin (gr/dL) 3.73 ± 0.51 3.38 ± 0.51 0.000
VC: Valvular Calcification; STR: Stroke; AF: Atrial Fibrillation
Table 2 – Echocardiographic parameters
Sin CV 
(n = 128)
Con CV 
(n = 128)
p
LV mass/BS (gr/m2) 156.2 ± 51.5 175.2 ± 52.3 0.005
LVEF % 65.5 ± 8.8 64.6 ± 6.9 0.460
LA dimension (mm) 39.55 ± 7.4 43.2 ± 7.5 0.000
E/A ratio in mitral  
filling flow
0.97 ± 0.45 0.79 ± 0.36 0.001
VC: Valvular Calcification; LV/BS: Left Ventricle/Body Surface; LVEF: 
Left Ventricular Ejection Fraction; LA: Left Atrium
Table 3 – Factors associated with the presence of VC at 
the start of dialysis. Logistic Regression Analysis
Odds ratio 95% CI p
Age 1.110 1.073-1.148 0.000
Albumin 0.29 0.14-0.61 0.001
Table 4 – Patients who had the event 
(MI, stroke and/or death from cardiovascular causes)
Patients with 
an event 
(n = 68)
Patients with 
no event 
(n = 188)
p
Age (years) 72,2 ± 9,8 62,5 ± 16,9 0.000
Diabetes (%) 41,2 23,9 0.007
Prior coronary artery disease 
and/or stroke (%)
30,9 9 0.000
AF (%) 17 (25) 14 (7,4) 0.000
VC (%) 51 (75) 77 (41) 0.000
Creatinine (mg/dL) 6,1 ± 1,8 6,9 ± 2,5 0.01
Pulse Pressure 60,5 ± 20,1 54,3 ± 21,5 0.034
LV mass (g/m2) 182,3 ± 61,4 159,5 ± 48 0.009
LA (mm) 43,4 ± 7,6 40,6 ± 7,5 0.011
LVEF % 61,9 ± 10,2 66,2 ± 8,6 0.001
AF: Atrial Fibrillation; VC: Valvular Calcification; LV: Left Ventricle; 
LA: Left Atrium; LVEF: Left Ventricular Ejection Fraction
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Discussion
The results of this study show that there is a high prevalence 
of VC in patients who start dialysis and that the presence of 
VC is associated with the occurrence of cardiovascular events 
and mortality in the course of follow-up. In the last decade, 
the scientific literature has shown that the frequency of VC 
(aortic, mitral, or both) in CKD is high. In the Framingham 
study, CKD (11% of patients with glomerular filtration rate < 
40 mL/min) increased the risk of mitral valve calcification by 
60%, although not aortic calcification1. Another study did not 
find an association between glomerular filtration rate < 60 
mL/min and aortic valve calcification, but it did find an asso-
ciation with mitral valve calcification in diabetic patients 
only2. Most of the information about VC is from prevalent 
dialysis population studies, with a prevalence ranging from 
30 to 70% of patients on both peritoneal dialysis3,2 and hae-
modialysis4,5,11. However, studies of patients who initiate 
dialysis are less frequent. A recent published study of incident 
dialysis patients in Japan showed a VC prevalence of 57.7%, 
and dialysis technique. The factors independently associated 
with the occurrence of the endpoint of the study were the 
presence of VC at the start of dialysis, older age, and prior 
diagnoses of AF, coronary artery disease, and/or stroke 
(Table 5).
To assess whether VC severity increased the risk for end-
point events, the same analysis was performed for the cal-
cification grades. For mild-moderate grade VC, the results 
were the following: HR 1.780 (95% CI 0.953–3.346, p = 0.07). 
Results for severe grade VC were: HR 4.517 (95% CI: 1.827–
11.809, p = 0.02).
80
70
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30
20
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0
Absent Mild-Moderate Severe
13.2Percentage
of events
37.5 75
17 (n=128) 45 (n=120) 6 (n=8) 
Figure 1 – Event-free survival (MI, stroke and/or death from cardiovascular causes); Kaplan-Meier Curves 
A: all patients; B: patients with no diagnosis of coronary artery disease, stroke or AF at the start of dialysis; VC: valvular 
calcification
Figure 2 – Event occurrence (MI, stroke and/or death from 
cardiovascular causes) by VC grade. 
VC: absent vs. mild-moderate, p = 0.000; absent vs. severe, 
p = 0.000; mild-moderate vs. severe, p = 0.036
Table 5 – Predictive factors for event occurrence 
(MI, stroke and/or death from cardiovascular causes). 
Cox Regression Analysis
Hazard ratio 95% CI p
Age 1.028 1.002-1.055 0.037
Valvular calcifications 1.996 1.077-3.700 0.028
Coronary artery disease and/
or stroke
1.979 1.111-3.527 0.021
Atrial Fibrillation 2.475 1.331-4.602 0.004
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adjusted for age and inflammatory markers16 or adjusted for 
prior cardiovascular events11. A study of asymptomatic prev-
alent dialysis patients (69% haemodialysis) at high risk for 
cardiovascular disease, segmental alterations in myocardial 
contractility and LVEF < 40% demonstrated an association 
between VC and the presence of inducible myocardial isch-
aemia; this suggests that VC may be a marker for silent myo-
cardial ischaemia risk in this population25.
In this study, VC was a predictor variable for the occur-
rence of MI, stroke and/or death from cardiovascular causes. 
There were more severe VC events than mild-moderate events 
(Figure 2). In the multivariate analysis adjusted for all the 
included variables, the mild-moderate grade was observed at 
the limit of statistical significance as a predictor variable for 
endpoint events. 
The availability of simple tools is important to assess car-
diovascular risk. In studies conducted in our institution, the 
history of cardiovascular events recorded in medical records, 
data from exploratory tests and electrocardiograms were use-
ful to predict cardiovascular risk in our population on dialy-
sis26,27,28,29. Echocardiography is a safe, low-cost, widely 
available technique and a simple tool that adds value to the 
results of this study.
In summary, at the start of a dialysis programme, a high 
proportion of patients have VC. This fact doubles the risk of 
MI, stroke and/or death from cardiovascular causes during 
the course of dialysis. The magnitude of this risk is similar to 
that of cardiovascular disease or the presence of AF before 
the start of dialysis.
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for an age slightly younger than that of our study15. In another 
publication, the prevalence of VC at the start of dialysis was 
35.6% for patients 15 years younger than our patients16.
In our study, older age and lower levels of albumin (an 
inflammatory and malnutrition marker) were independently 
associated with the presence of VC. Age is an important fac-
tor associated with VC3,6, along with inflammatory markers. 
In prevalent dialysis patients, an association was demon-
strated between VC and inflammatory markers, such as 2 
microglobulin, cytokines, CRP and others like fetuin A5,15,9,8.
In the baseline assessment, patients with VC had a higher 
incidence of history of cardiovascular events, AF and diabetes, 
along with higher blood pressure and pulse pressure as well 
as structural alterations such as left ventricular hypertrophy 
and greater diastolic dysfunction. In studies of patients with 
VC on dialysis, cardiovascular disease and structural cardiac 
alterations have not always been assessed. In prevalent 
patients, VC has been associated with coronary artery dis-
ease10, a history of cardiovascular events and left ventricular 
hypertrophy11, and carotid intima-media thickness13. In the 
Japanese study of events during dialysis, cardiovascular 
events and structural cardiac alterations were not analysed15. 
In another study, patients with prior coronary artery events 
were excluded16. 
VC was not associated with alterations in bone-mineral 
metabolism, which is similar to other studies of incident dial-
ysis patients15,6; some studies of prevalent patients have 
shown an association between VC and some biochemical 
alterations in calcium/phosphorous metabolism17,18. A possi-
ble explanation is the better phosphorous control in incident 
patients with residual renal function, which does not exclude 
the involvement of bone-mineral metabolism alterations in 
the genesis of VC. The pathogenesis of VC and vascular calci-
fication is not clear, although they share mechanisms; in 
patients on dialysis, a correlation between VC and vascular 
calcification has been shown19. CKD involves alterations in 
calcium/phosphorous metabolism and bone remodelling, 
inflammation and imbalance between inducers and inhibitors 
of calcification. The final result is the phenotypical change of 
cells in valvular and vascular structures to osteoblasts20,21. 
Both in experimental studies22 and clinical studies23, an 
inverse correlation has been shown between vascular and 
valvular calcification with the loss of bone mineralization, 
and, in patients on dialysis, it has been shown that the pres-
ence of VC is associated with a greater progression of coro-
nary calcification, measured by multi-slice CT16. In the 
ADVANCE study, patients treated with the calcimimetic 
cinacalcet showed less increase in the progression of aortic 
valve calcification, which indicates the involvement of min-
eral metabolism disorders in VC24.
Another matter is the importance of VC as a predictive 
factor for cardiovascular risk in patients on dialysis. In stud-
ies of prevalent haemodialysis patients, VC was a predictor 
variable for all-cause mortality4. In prevalent peritoneal dial-
ysis patients, it was a predictor for cardiovascular mortality 
and mortality from any cause; this is similar to the risk posed 
by the history of atherosclerotic events, which establishes it 
as a cardiovascular disease marker3. In other studies, VC was 
not a predictor of mortality in the multivariate analysis 
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